A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
Top Cited Papers
- 1 October 2008
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 135 (4) , 1130-1141
- https://doi.org/10.1053/j.gastro.2008.07.014
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Certolizumab Pegol for the Treatment of Crohn's DiseaseNew England Journal of Medicine, 2007
- Maintenance Therapy with Certolizumab Pegol for Crohn's DiseaseNew England Journal of Medicine, 2007
- Adalimumab Induction Therapy for Crohn Disease Previously Treated with InfliximabAnnals of Internal Medicine, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- European evidence based consensus on the diagnosis and management of Crohn's disease: current managementGut, 2006
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s diseaseGastroenterology, 2004
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Management of Crohn's disease in adultsAmerican Journal of Gastroenterology, 2001
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997